Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili) - Oncologia Medica
Welcome,         Profile    Billing    Logout  
 2 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Buglione, Michela
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
PRO-EPI, NCT03340272: PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.

Active, not recruiting
N/A
1000
Europe
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Takeda
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
02/20
02/23
Bastia, Michela Buglione di Monale e
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
Wang, Buhai
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
NCT06065813: Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Recruiting
2
20
RoW
Toripalimab, JS001, Conventional segmental radiotherapy, opreation
Northern Jiangsu Province People's Hospital, Shanghai Junshi Bioscience Co., Ltd.
Non-small Cell Lung Cancer, Neoadjuvant Therapy, Radiotherapy, Immunotherapy
05/26
05/26
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

Recruiting
1/2
156
RoW
JS111(AP-L1898 Capsules)
Suzhou Junjing BioSciences Co., Ltd.
Lung Cancer
06/24
08/24
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Active, not recruiting
1/2
376
RoW
TJ004309, Toripalimab
TJ Biopharma Co., Ltd.
Advanced Solid Tumor
12/24
12/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Buglione, Michela
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
PRO-EPI, NCT03340272: PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.

Active, not recruiting
N/A
1000
Europe
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Takeda
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
02/20
02/23
Bastia, Michela Buglione di Monale e
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
Wang, Buhai
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
NCT06065813: Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Recruiting
2
20
RoW
Toripalimab, JS001, Conventional segmental radiotherapy, opreation
Northern Jiangsu Province People's Hospital, Shanghai Junshi Bioscience Co., Ltd.
Non-small Cell Lung Cancer, Neoadjuvant Therapy, Radiotherapy, Immunotherapy
05/26
05/26
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

Recruiting
1/2
156
RoW
JS111(AP-L1898 Capsules)
Suzhou Junjing BioSciences Co., Ltd.
Lung Cancer
06/24
08/24
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Active, not recruiting
1/2
376
RoW
TJ004309, Toripalimab
TJ Biopharma Co., Ltd.
Advanced Solid Tumor
12/24
12/24

Download Options